Heme Synthesis and Porphyrias — MCQs

10 questions

A patient's relatives sent a message on social media to the consulting doctor, mentioning that the patient's urinary coproporphyrin test is positive. What is the probable cause?

Investigation of choice for confirming Henoch Schönlein Purpura is

A 35-year-old construction worker presents with a 3-month history of abdominal pain, fatigue, and recent onset of numbness and tingling in his hands and feet. He works in renovation of old buildings. Physical examination reveals mild pallor and decreased sensation in a stocking-glove distribution. Blood tests show microcytic anemia with basophilic stippling on peripheral smear. What is the most likely diagnosis?

A useful screening test for lead is measurement of which of the following?

In G6PD deficiency, which enzyme's function is MOST directly impaired due to decreased NADPH availability, leading to reduced protection against oxidative stress?

Aminolevulinic acid is a metabolic product in the synthesis of -

Which of the following is not classified as a cutaneous porphyria?

A 28-year-old woman comes to the emergency department because of a 2-day history of dark urine, increasing abdominal pain, and a tingling sensation in her arms and legs. She has a history of epilepsy. Her current medication is phenytoin. She is nauseated and confused. Following the administration of hemin and glucose, her symptoms improve. The beneficial effect of this treatment is most likely due to inhibition of which of the following enzymes?

All are involved in bilirubin metabolism except?

Q10

What is the rate-limiting enzyme in heme synthesis?

Heme Synthesis and Porphyrias Indian Medical PG Practice Questions and MCQs

Question 1: A patient's relatives sent a message on social media to the consulting doctor, mentioning that the patient's urinary coproporphyrin test is positive. What is the probable cause?

A. Lead poisoning (Correct Answer)
B. Asbestosis
C. Silicosis
D. Mercury poisoning
E. Arsenic poisoning

Explanation: ***Lead poisoning*** - **Lead poisoning** is associated with an increase in **urinary coproporphyrin III**, as lead inhibits the enzyme **coproporphyrinogen oxidase** in the heme synthesis pathway. - This leads to the accumulation and excretion of **coproporphyrin III** in the urine, making it a valuable biomarker for lead exposure. *Asbestosis* - **Asbestosis** is a chronic lung disease caused by inhaling **asbestos fibers**, leading to diffuse interstitial fibrosis. - It does not directly affect the **heme synthesis pathway** or cause an increase in urinary coproporphyrins. *Silicosis* - **Silicosis** is a chronic occupational lung disease caused by inhaling **crystalline silica dust**, resulting in pulmonary fibrosis. - It is not associated with alterations in **porphyrin metabolism** or increased urinary coproporphyrin levels. *Mercury poisoning* - While **mercury poisoning** can affect various organ systems, including renal and neurological, it is not primarily associated with disturbances in the **heme synthesis pathway** or elevated urinary coproporphyrins. - **Mercury poisoning** often manifests with symptoms like **tremors**, **neurological deficits**, and **kidney damage**. *Arsenic poisoning* - **Arsenic poisoning** causes a variety of systemic effects including gastrointestinal symptoms, peripheral neuropathy, and skin changes (hyperpigmentation, hyperkeratosis). - Unlike lead poisoning, **arsenic does not significantly elevate urinary coproporphyrin III** levels, making it distinguishable from lead toxicity through this biomarker.

Question 2: Investigation of choice for confirming Henoch Schönlein Purpura is

A. Serum IgA levels
B. CRP levels
C. DTPA
D. Renal Biopsy (Correct Answer)

Explanation: ***Renal Biopsy*** - **Biopsy (renal or skin)** showing **IgA deposition** is the **confirmatory investigation** for Henoch-Schönlein Purpura (HSP) when histological confirmation is needed [1]. - **Renal biopsy** demonstrates characteristic **IgA-dominant immune deposits** in the mesangium and glomerular capillaries, along with **mesangial proliferation** [1]. - While HSP is primarily a **clinical diagnosis** based on palpable purpura, age < 20 years, abdominal pain, and renal involvement, biopsy provides **definitive confirmation** in atypical presentations or when diagnosis is uncertain. - Immunofluorescence showing **IgA deposition** is the pathognomonic finding [1]. *Serum IgA levels* - Serum IgA levels may be elevated in approximately **50% of HSP cases**, but this is **neither sensitive nor specific**. - **Normal serum IgA does NOT exclude HSP**, making it unreliable as a confirmatory test. - Elevated IgA can occur in many other conditions (IgA nephropathy without vasculitis, liver disease, infections). - Provides only supportive evidence, not confirmation. *CRP levels* - **C-reactive protein (CRP)** is a **non-specific inflammatory marker** that may be elevated in HSP. - Cannot distinguish HSP from other inflammatory or infectious conditions. - Has no role in confirming the diagnosis. *DTPA* - **DTPA scan** assesses **renal perfusion and function** but does not provide diagnostic information about the underlying pathology. - Cannot detect the characteristic **IgA-mediated vasculitis** of HSP. - Not useful for confirming the diagnosis. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 526-527.

Question 3: A 35-year-old construction worker presents with a 3-month history of abdominal pain, fatigue, and recent onset of numbness and tingling in his hands and feet. He works in renovation of old buildings. Physical examination reveals mild pallor and decreased sensation in a stocking-glove distribution. Blood tests show microcytic anemia with basophilic stippling on peripheral smear. What is the most likely diagnosis?

A. Coeliac disease
B. Sickle cell disease
C. Lead poisoning (Correct Answer)
D. Hookworm infestation

Explanation: **Lead poisoning** - The patient's occupation in **renovating old buildings** poses a significant risk for lead exposure [1]. - Classic symptoms of lead poisoning, such as **abdominal pain** [1], **fatigue**, **peripheral neuropathy** (numbness/tingling in stocking-glove distribution) [2], **pallor** [2], **microcytic anemia**, and **basophilic stippling** [1], are all present. *Coeliac disease* - While it can cause **abdominal pain** and **fatigue** due to malabsorption, it typically leads to **iron deficiency anemia**. - **Neuropathy** is less common and **basophilic stippling** is not a feature of coeliac disease. *Sickle cell disease* - Causes **hemolytic anemia** and painful crises, but is a genetic disorder typically diagnosed in childhood and presents with different symptoms. - While it can present with **fatigue** and **pallor**, **basophilic stippling** is not typical, and neuropathy in a stocking-glove distribution is rare. *Hookworm infestation* - Primarily causes **iron deficiency anemia** due to chronic blood loss from the gut, leading to **fatigue** and **pallor**. - It does not typically cause **basophilic stippling** or prominent **peripheral neuropathy** as described.

Question 4: A useful screening test for lead is measurement of which of the following?

A. Coproporphyrin in urine
B. Free erythrocyte protoporphyrin (FEP) (Correct Answer)
C. Aminolevulinic acid in urine
D. Lead in morning urine sample

Explanation: ***Free erythrocyte protoporphyrin (FEP)*** - **FEP (or Zinc Protoporphyrin - ZPP)** is the **most widely used screening test** for lead poisoning, particularly in occupational health and community screening programs. - Lead inhibits **ferrochelatase**, the enzyme that incorporates iron into protoporphyrin IX to form heme, resulting in accumulation of **protoporphyrin** in erythrocytes. - FEP levels reflect **chronic lead exposure** and remain elevated for the lifespan of the red blood cell (~120 days), making it an excellent screening tool. - It is **non-invasive** (can use capillary blood), **cost-effective**, and **widely available**. - Note: FEP is also elevated in **iron deficiency**, so elevated values should be followed up with blood lead levels for confirmation. *Coproporphyrin in urine* - Urinary coproporphyrin is elevated in lead poisoning due to inhibition of **coproporphyrinogen oxidase** in the heme synthesis pathway. - While it can be used as a **confirmatory test**, it is **less specific** than FEP and not the primary screening test. - It is also elevated in other conditions like liver disease and alcoholism. *Aminolevulinic acid in urine* - Urinary **δ-aminolevulinic acid (ALA)** is elevated in lead poisoning because lead inhibits **ALA dehydratase**, the second enzyme in heme synthesis. - This is a **sensitive indicator** of lead exposure and is often used as a **supplementary screening test** alongside FEP. - However, FEP remains the more commonly used initial screening test in practice. *Lead in morning urine sample* - Urine lead measurement has significant **day-to-day variability** and is not a reliable screening test. - Most lead is stored in **bone** (90% in adults), not excreted in urine. - **Blood lead levels (BLL)** are the gold standard for diagnosis, not urinary lead measurements.

Question 5: In G6PD deficiency, which enzyme's function is MOST directly impaired due to decreased NADPH availability, leading to reduced protection against oxidative stress?

A. Catalase
B. Pyruvate kinase
C. Superoxide dismutase
D. Glutathione reductase (Correct Answer)

Explanation: ***Glutathione reductase*** - **G6PD deficiency** impairs the production of **NADPH** through the pentose phosphate pathway - **Glutathione reductase** is NADPH-dependent and reduces oxidized glutathione (GSSG) back to reduced glutathione (GSH) - Without adequate NADPH, glutathione reductase cannot maintain sufficient **GSH levels**, which is the primary antioxidant protecting RBCs from oxidative damage - This explains why G6PD deficiency leads to **hemolysis** when exposed to oxidative stressors (antimalarials, sulfonamides, fava beans) *Catalase* - **Catalase** decomposes hydrogen peroxide to water and oxygen, protecting cells from oxidative damage - While important for antioxidant defense, catalase does **not require NADPH** for its function - Its activity is not directly impaired by decreased NADPH in G6PD deficiency *Pyruvate kinase* - **Pyruvate kinase** catalyzes the final step of **glycolysis**, producing ATP - Its function is **completely independent** of NADPH levels - Pyruvate kinase deficiency causes a separate hemolytic anemia unrelated to oxidative stress or G6PD deficiency *Superoxide dismutase* - **Superoxide dismutase (SOD)** converts superoxide radicals to hydrogen peroxide and oxygen - SOD functions **independently of NADPH** and uses metal cofactors (Cu/Zn or Mn) - While part of antioxidant defense, it is not directly affected by G6PD deficiency

Question 6: Aminolevulinic acid is a metabolic product in the synthesis of -

A. Tryptophan
B. Collagen
C. Glycosaminoglycans
D. Heme (Correct Answer)

Explanation: ***Heme*** - **Aminolevulinic acid (ALA)** is the first committed precursor in the **heme biosynthesis pathway**. - Its formation from succinyl CoA and glycine is catalyzed by **ALA synthase**, which is the rate-limiting enzyme. *Tryptophan* - **Tryptophan** is an essential amino acid and a precursor for molecules like **serotonin**, **melatonin**, and **niacin**. - Its synthesis does not involve aminolevulinic acid. *Collagen* - **Collagen** is a structural protein primarily composed of amino acids such as **glycine, proline, and hydroxyproline**. - Its synthesis pathway is distinct and does not utilize aminolevulinic acid. *Glycosaminoglycans* - **Glycosaminoglycans (GAGs)** are long, unbranched polysaccharides consisting of repeating disaccharide units, significant components of the **extracellular matrix**. - Their synthesis involves various sugars and enzymes, but not aminolevulinic acid.

Question 7: Which of the following is not classified as a cutaneous porphyria?

A. Congenital erythropoietic porphyria
B. Erythropoietic protoporphyria
C. Sideroblastic anemia (Correct Answer)
D. Hereditary coproporphyria

Explanation: ***Hereditary coproporphyria*** - This condition is primarily associated with **acute episodes** and **neuropathy**, rather than cutaneous manifestations. [2] - Unlike cutaneous porphyrias, symptoms are more systemic and do not commonly present with **skin lesions**. Although skin features can occur in some instances, they mimic porphyria cutanea tarda. [2] *Congenital erythropoeitic porphyria* - Characterized by severe **cutaneous symptoms** such as blistering and photosensitivity due to **skin exposure**. - Patients exhibit notable **facial disfigurement** and can have **hemolytic anemia**, aligning it clearly with the cutaneous forms of porphyria. *Sideroblastic anemia* - This condition involves issues with **hemoglobin synthesis** and does not fit the porphyria classification. [1] - It primarily presents with **microcytic anemia**, and the symptoms are primarily hematological, not cutaneous. [1] *Erythropoeitic porphyria* - Characterized by **severe photosensitivity** and skin manifestations, similar to congenital erythropoeitic porphyria. [1] - Patients may develop **blisters** and **hyperpigmentation** upon sun exposure, categorizing it among cutaneous porphyrias. [2]

Question 8: A 28-year-old woman comes to the emergency department because of a 2-day history of dark urine, increasing abdominal pain, and a tingling sensation in her arms and legs. She has a history of epilepsy. Her current medication is phenytoin. She is nauseated and confused. Following the administration of hemin and glucose, her symptoms improve. The beneficial effect of this treatment is most likely due to inhibition of which of the following enzymes?

A. Uroporphyrinogen decarboxylase
B. Porphobilinogen deaminase
C. Aminolevulinic acid synthase (Correct Answer)
D. Ferrochelatase
E. Aminolevulinate dehydratase

Explanation: ***Aminolevulinic acid synthase*** - The patient's symptoms (dark urine, abdominal pain, neurological symptoms like tingling and confusion) and improvement with **hemin** and **glucose** strongly suggest an acute porphyria, most likely **acute intermittent porphyria (AIP)**. - **Hemin** and **glucose** work by downregulating **aminolevulinic acid synthase (ALAS)**, the rate-limiting enzyme in heme synthesis, thereby reducing the production of neurotoxic porphyrin precursors (ALA and PBG). *Uroporphyrinogen decarboxylase* - Deficiency in **uroporphyrinogen decarboxylase** is associated with **porphyria cutanea tarda (PCT)**, which primarily causes cutaneous photosensitivity, not acute neurovisceral symptoms. - PCT does not typically present with acute life-threatening attacks or respond acutely to hemin and glucose. *Porphobilinogen deaminase* - Deficiency of **porphobilinogen deaminase (PBG deaminase)** is the underlying genetic defect in **acute intermittent porphyria (AIP)**. - While this is the enzyme deficient in AIP, hemin and glucose don't directly inhibit this enzyme; their action is upstream on ALAS to prevent the accumulation of toxic precursors. *Ferrochelatase* - Deficiency of **ferrochelatase** causes **erythropoietic protoporphyria (EPP)**, leading to painful photosensitivity and sometimes liver disease, but generally not acute neurovisceral attacks. - The symptoms presented and the treatment response are not consistent with EPP. *Aminolevulinic acid dehydratase* - Deficiency in **aminolevulinic acid dehydratase** causes **ALA dehydratase deficiency porphyria**, a very rare form of porphyria with symptoms similar to lead poisoning. - While it involves elevated ALA, it's less common than AIP, and the broad clinical picture with the dramatic response to hemin points more directly to the regulation of ALAS.

Question 9: All are involved in bilirubin metabolism except?

A. Biliverdin reductase
B. Heme oxygenase
C. Glucuronyl transferase
D. ALA synthase (Correct Answer)

Explanation: ***ALA synthase*** - **ALA synthase** is the enzyme responsible for the first committed step in **heme synthesis**, not bilirubin metabolism. - It catalyzes the condensation of **succinyl CoA** and **glycine** to form δ-aminolevulinic acid (ALA). *Biliverdin reductase* - This enzyme catalyzes the conversion of **biliverdin**, a green pigment, into **unconjugated bilirubin**, a yellow pigment. - It is an essential step in the breakdown pathway of **heme** into bilirubin. *Heme oxygenase* - **Heme oxygenase** is the enzyme that cleaves the **heme ring** to form **biliverdin**, releasing carbon monoxide and iron. - This is the initial and rate-limiting step in **heme catabolism**, leading to bilirubin formation. *Glucuronyl transferase* - **UDP-glucuronyl transferase** (UGT) conjugates unconjugated bilirubin with **glucuronic acid** in the liver. - This conjugation process makes bilirubin water-soluble, allowing its excretion into the **bile**.

Question 10: What is the rate-limiting enzyme in heme synthesis?

A. ALA synthase (Correct Answer)
B. HMG CoA reductase
C. ALA dehydratase
D. Uroporphyrinogen 1 synthase

Explanation: ***ALA synthase*** - **Aminolevulinate synthase** (ALA synthase) is the first and **rate-limiting enzyme** in the heme synthesis pathway. - Its activity is tightly regulated, and its overexpression or deficiency can lead to disorders like **acute intermittent porphyria**. *Hmg coa reductase* - **HMG-CoA reductase** is the **rate-limiting enzyme** in the **cholesterol biosynthesis pathway**, not heme synthesis. - It is the target enzyme for statin medications, which lower cholesterol levels. *ALA dehydratase* - **ALA dehydratase** (also known as porphobilinogen synthase) is the second enzyme in the heme synthesis pathway, responsible for converting two molecules of **ALA to porphobilinogen**. - While critical, it is not the rate-limiting step; inhibition of this enzyme can lead to **lead poisoning**. *Uroporphyrinogen 1 synthase* - **Uroporphyrinogen I synthase** (also called hydroxymethylbilane synthase or porphobilinogen deaminase) catalyzes the formation of **hydroxymethylbilane** from four molecules of **porphobilinogen**. - A deficiency in this enzyme is associated with **acute intermittent porphyria**, but it is not the rate-limiting enzyme of the overall pathway.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free